South Africa: Supreme Court of Appeal

You are here:
SAFLII >>
Databases >>
South Africa: Supreme Court of Appeal >>
2004 >>
[2004] ZASCA 122
| Noteup
| LawCite
Pharmaceutical Society of South Africa and Others v Minister of Health and Another; New Clicks South Africa (Pty) Limited v Tshabalala-Msimang NO and Another (542/2004, 543/2004) [2004] ZASCA 122; 2005 (3) SA 238 (SCA); [2005] 1 All SA 326 (SCA); 2005 (6) BCLR 576 (SCA) (20 December 2004)
Download original files | Links to summary |
Last Updated: 8 June 2005
THE SUPREME COURT OF APPEAL
OF SOUTH
AFRICA
Reportable
Case Nos 542/04
543/04
In the matter between:
PHARMACEUTICAL SOCIETY OF SOUTH AFRICA
AND OTHERS
Appellants
and
THE MINISTER OF HEALTH AND ANOTHER
Respondents
NEW CLICKS SOUTH AFRICA (PTY) LIMITED Appellant
and
DR MANTO TSHABALALA-MSIMANG NO
AND ANOTHER Respondents
Coram: HARMS, NAVSA, MTHIYANE, BRAND and CLOETE JJA
Heard: 30 November and 1 December 2004
Delivered: 20 December 2004
Subject: Medicines and Related Substances Act – Regulations relating to a Transparent Pricing System for Medicines and Scheduled Substances – validity – legality (ultra vires) – Leave to appeal – failure of court of first instance to make order within reasonable time – effect.
J U D G M E N T
HARMS JA/
HARMS JA
INTRODUCTION
[1] The applicants are applying for leave
to appeal. In issue is the validity of the ‘Regulations relating to a
Transparent
Pricing System for Medicines and Scheduled
Substances’.[1] They were
promulgated on 30 April 2004 by the Minister of Health in terms of s 22G of the
Medicines and Related Substances Act 101
of 1965 (‘the Medicines
Act’). The section permits the minister to make regulations on the
recommendation of a pricing
committee established by the section. The
regulations may, essentially, provide for a transparent pricing system for
manufacturers
of medicines and may prescribe a dispensing fee. Manufacturers are
obliged to charge the same price to all; discounts are prohibited;
manufacturers
must publish their ‘single exit price’; no one in the supply chain
may charge more than the single exit
price; pharmacists and other licensed
health professionals may, however, add the prescribed ‘appropriate
dispensing fee’,
but no more. The regulations under attack provide for a
pricing system that defines and controls the single exit price for manufacturers
and importers and for a dispensing fee, which, for pharmacists amounts to either
16% of the exit price (if it is less than R100)
or R16 (if more than R100)
without a medical prescription. If there is a prescription the figures are 26%
(if it is less than R100)
and R26 (if more than R100, whether R100 or R1000).
The major issues are whether these fees are ‘appropriate’ and
whether
the regulation of the single exit price is legal.
[2] There are
two applications. In one the first applicant is the Pharmaceutical Society of
South Africa (‘PSSA’), joined
by six other entities that own
pharmacies. The other is by New Clicks SA (Pty) Ltd, the owner of 86 pharmacies.
The respondents in
both applications are first, the Minister of Health and
second, Prof D McIntyre, cited in the court below under uniform rule 53 in
her
capacity as chairperson of the pricing committee. At the appeal stage the
Treatment Action Campaign joined the proceedings as
amicus
curiae.
HISTORY OF THE PROCEEDINGS
[3] The applicants,
in separate review applications, applied in the Cape High Court for the setting
aside of the regulations. Due
to the urgency of the matters, the court granted
interim relief by agreement on 1
June.[2] In terms of the order the
regulations were suspended pending the final determination of the reviews and
the parties placed on terms
for filing papers. At the behest of the respondents
early hearing dates were allocated, namely 17 and 18 June. The matters were
heard by a full bench as a court of first instance. Judgment was delivered on 27
August and the applications were dismissed (per
Yekiso J, Hlophe JP concurring;
Traverso DJP dissenting).
[4] Alleging that the dismissal of their
review applications (which brought the suspension of the regulations to an end)
did not remove
the urgency, the applicants immediately sought leave to appeal
from the court below by filing their applications on the next court
day, 30
August. These notices did not raise any issues not covered by the two judgments.
The applicants then requested an early hearing
date but the court ruled that the
date had to suit respondents’ counsel. The applications were eventually
heard on 20 September
but instead of making an ex tempore order, as is
the practice in matters of this kind, the court reserved judgment.
[5] Some five weeks later, on 20 October, the applicants in the PSSA
application wrote to the registrar of the court below, with a
request to
establish whether the judge president, who had intimated at the hearing that he
would write the judgment, would indicate
when a ruling might be expected (even
if reasons were to follow). Neither the registrar nor the judge president
responded. The applicants
thereafter decided to file the present applications
with this court. They intended as a gesture of courtesy to meet with the judge
president to inform him in advance but he was unable – for unknown reasons
– to meet them. On 11 November the present
applications were
filed.
[6] The next day the judge president became available for the
courtesy call and, according to the state attorney, he told those present
that
the second draft of the judgment was in the process of being typed. He enquired
of them whether, in the light of the applications,
he was expected to stop the
process and dispense with the need to finalise the judgment. No one responded
and he then said that he
would continue to finalise the judgment. Once again, no
indication of when judgment was to be delivered was given and no explanation
for
the delay provided. If there were compelling reasons for the delay, one would
have expected some explanation.[3]
[7] In the meantime and pursuant to the filing of the present
applications I had invited the parties to a conference in chambers to
enable me
under delegated powers to issue the necessary directions in terms of SCA rule 11
as to the manner in which the applications
were to be dealt with. At the request
of the respondents the meeting took place on 17 November, two days later than
intended, and
the ruling was issued early the next morning after consultation
with the head of court and the members of the panel to whom the applications
were allocated. The ruling was in the customary
form:[4] the hearing of the
applications was consolidated, the applications were referred for oral argument
on 30 November and 1 December
in terms of s 21(3)(c)(ii) of the Supreme Court
Act 59 of 1959, the parties were to be prepared (if called upon to do so) to
address
the court on the merits, and the respondents were to file any affidavits
and heads of argument if and when
convenient.[5]
[8] On 29
November, the eve of the hearing before this court, the judge president gave
notice to the parties that judgment would be
delivered on 3 December. In the
event it was. Hlophe JP (Yekiso J concurring) refused leave whilst Traverso DJP
would have done otherwise.
Why it took three weeks to type or check a second
draft of a judgment that ultimately ran to thirteen well-spaced typed pages we
have not been told. As this court once
said:[6]
‘Much more than a
matter of mere courtesy is involved. By such conduct the administration of
justice is hampered, and may be
seriously hampered, by an arbiter of justice
himself, whose responsibility it is to render it effective and not add judicial
remissness
to its already irksome delays.’
[9] Three issue arise
from the present applications: (a) should they be dealt with as a matter of
urgency; (b) were the applicants
entitled to approach this court for leave to
appeal where the court of first instance had not yet ruled on their applications
(the
so-called jurisdiction point) and (c) if so, do the applicants have
reasonable prospects of success on appeal? The respondents raised
a further
procedural issue, namely whether the first two issues should be separated from
the third, insisting that this court should
deal with the application piecemeal,
and not as a whole.
URGENCY
[10] In the court below (as
mentioned) the case was dealt with by agreement between the parties and by the
court as one of urgency
until judgment on 27 August. Nothing has since changed
except that the respondents were successful. The only point made by the
respondents
of any consequence is that the matter is no longer urgent; had it
been urgent, the applicants would have applied for leave to appeal
to the
Constitutional Court; instead they applied for leave to this
court.[7] One gained the impression
that the respondents believe (a view shared by the court below as will appear
later) that since there are
constitutional issues only the Constitutional Court
should deal with the matter. The choice of forum was that of the applicants
alone.
If properly engaged, this court has a constitutional duty to deal with a
matter and deal with it expeditiously. This court does not
have the power to
divert cases to the Constitutional Court. In any event, and this the applicants
allege is their dilemma, the Constitutional
Court is entitled to refuse to hear
appeals directly and may require that they first be heard by this court.
Therefore, they say,
it was prudent for them to take the present
route.
[11] Although not raised with reference to any facts in the
affidavits opposing the applications before us, respondents’ counsel
objected to the present proceedings and submitted that they were procedurally
unfair because of the limited time allowed to enable
them to prepare on the
merits; eight court days were allegedly
insufficient.[8]
[12] In the
court below the respondents were able to deal with both cases within
exceptionally short periods, most of their own choosing.
They prepared lengthy
answering affidavits by 31 May (amplified by 9 June), taking into account the
applications were only served
on 24 and 27 May, and were in court on 1 June for
the preliminary hearing. And they were ready to argue on 17 June, three ordinary
days after the replying and eight ordinary days after the answering affidavits
had been filed. They were also in a position to file
heads of argument, so full
that the court below was able to dispose of argument by four sets of counsel
within a day and a half,
despite the fact that the combined record ran to about
4000 pages.
[13] The respondents’ submissions in this regard,
sadly, were but a smokescreen. Already at the meeting on 17 November with
me,
the respondents’ counsel insisted emphatically on a separation of issues
and stated that their clients would not instruct
counsel to deal with the
merits. During oral argument before us, the respondents’ lead counsel was
specifically and repeatedly
asked whether they required a postponement in order
to prepare argument on the merits. The questions did not elicit a response. When
asked whether the respondents could provide a date convenient to them for
argument on the merits, the question failed to extract
a reaction. When asked
whether they needed an adjournment to consider a request for a postponement, yet
again, counsel did not reply
and simply proceeded to argue another
point.[9]
[14] This is
consistent with the attitude from the outset that the jurisdictional issue
should be dealt with separately. They had
a right, they said, to a separate
hearing. And they wished to exercise that right in order that, if we dismiss
their argument, they
could appeal. That is why they decided in advance not to
instruct counsel, why they refused – in spite of a request on 17 November
– to provide copies of the heads of argument used in the court below to
assist us in preparing for the hearing, and why they
were generally obstructive
in relation to each suggestion relating to an expedited
hearing.[10] As will become apparent
from the discussion on the merits, the issues are of national importance.
Because of uncertainty and confusion
created and the frustration of what was
intended, namely access to health care, it is imperative that the litigation
should be brought
to an early conclusion. There is accordingly no merit in the
respondents’ submission that the applications are not urgent or
that they
were prejudiced procedurally by an urgent hearing.
SEPARATION OF
ISSUES[11]
[15] In S v
Malinde 1990 (1) SA 57 (A) 67F-G it was said:
‘This Court is in
principle strongly opposed to the hearing of appeals in piecemeal fashion. . . .
An exception may be made,
however, where unusual circumstances call for such
procedure . . . or in “enkele gevalle van 'n besondere aard” . .
..’
The same applies to applications. Nicholas AJA proceeded to state
(at 68C-E):
‘Substantial grounds should exist for the exercise of the
power. The basis of the jurisdiction is convenience – the convenience
not
only of the parties but also of the Court. The advantages and disadvantages
likely to follow upon the granting of an order must
be weighed. If overall, and
with due regard to the divergent interests and considerations of convenience
affecting the parties, it
appears that the advantages would outweigh the
disadvantages, the Court would normally grant the application.’
He
concluded (at 86E) by saying that the court should not grant an application for
a separate hearing unless there appeared to be
a reasonable degree of likelihood
that the alleged advantages would in fact result.
[16] The respondents
have not sought to justify a separation of issues by filing an application
therefor. Instead, they claim a right
thereto and in this regard they cited
Chevron Engineering (Pty) Ltd v Nkambule 2003 (5) SA 206 (SCA) and
American Natural Soda Corporation v Competition Commission 2003 (5) SA
655 (SCA). They submitted that the separation of jurisdiction from other issues
is the normal procedure of this court. They are wrong.
Sometimes the issue is
dealt with separately but that usually depends on the nature of the application.
For instance, in American Natural Soda the application was for an order
declaring, inter alia, that the applicants were entitled to note an appeal while
in Chevron the applicant not only asked for leave to appeal but also for
directions in regard to the further prosecution and conduct of the
appeal.[12] In neither case was the
record before court nor did the question of separation of issues
arise.
[17] As said, the only reason the respondents advanced in support
of a separation was that they wished to appeal any unfavourable
ruling first,
which would have added to the delay. That reason is insufficient and does not
fulfil the requirements laid down in
S v Malinde. In addition, there are
the considerations alluded to in para 14 above, which militate against a
separation.
JURISDICTION
[18] The facts recited have a
material bearing on the next issue, namely, whether this court was entitled to
entertain the applications
for leave to appeal considering the fact that they
were launched before the court below had ruled on the applications before it.
The respondents submit not. The basis of their submission is that this court
does not have any jurisdiction in the absence of a ruling
by the lower court.
[19] As a starting point, this court does not have any original
jurisdiction.[13] Its jurisdiction
is derived from the Constitution and is principally limited to decide appeals
and issues connected with appeals
(which includes applications for leave to
appeal).[14] Although this court,
like the Constitutional Court and High Courts, has the inherent power to protect
and regulate its own process,
that ‘does not extend to the assumption of
jurisdiction not conferred upon it by
statute.’[15]
[20] This
principle requires some elucidation, which can be done with reference to the
cases just cited. In Moch the facts were these: s 150 of the Insolvency
Act 24 of 1936 does not permit an appeal against a provisional order of
sequestration. The applicant in that matter argued that this court could
bypass
the prohibition by the exercise of its inherent jurisdiction. It was in answer
to that submission that this court said that
the inherent power to regulate its
process does not extend to the assumption of jurisdiction not conferred upon it
by statute. In
S v Basson[16]
the issue was similar. The question was whether the Criminal Procedure Act 51 of
1977 gave the state a right to appeal the discharge of an accused on the merits.
If the Constitution or a statute does not provide for
such a right that is the
end of the matter and this court cannot assume the power. Neither case was
concerned with the instance where
there is a right of appeal subject to
procedural preconditions.
[21] Appeal jurisdiction of this court in
civil proceedings is derived from s 20(1) of the Supreme Court Act. This court
has jurisdiction
to hear appeals against judgments or orders in any civil
proceeding.[17] Section 20(4)(b)
contains certain conditions that apply to the present cases:
‘No appeal
shall lie against a judgment or order of the court of a provincial or local
division [read: high court] in any civil
proceedings . . .
except—
(a) . . . ;
(b) . . . with the leave of the court against
whose judgment or order the appeal is to be made or, where such leave has been
refused,
with the leave of the appellate division [read: Supreme Court of
Appeal].’
The purpose of para (b) is to protect this court against
baseless appeals and it does so by limiting appeals to those that have
reasonable
prospects of success.[18]
Prior to its amendment in 1982, the section gave a party in the position of the
applicants an untrammelled right of appeal to this
court.[19]
[22] Although
couched in the negative, these provisions mean that in civil proceedings
emanating from high courts, everyone has a
right of appeal against judgments or
orders. The right is not absolute since leave to appeal is required. Leave is a
condition for
exercising the right or, put differently, it is a jurisdictional
fact for an appeal. The court whose judgment is sought to be appealed
must first
be approached for leave.[20] If that
is granted, the condition is fulfilled. If it is refused, the party wishing to
appeal has a right to petition this court
for leave. That much is clear from
National Union of Metalworkers of SA v Jumbo Products CC [1996] ZASCA 87; 1996 (4) SA 735
(A) 740A-D where Corbett CJ said that –
‘no appeal lies to this
Court against the judgment on the merits or the judgment refusing condonation of
the late filing of
the application to the Court a quo for leave to appeal
except either where the Court a quo has itself granted leave to
appeal or where, the Court a quo having refused such leave, such leave
has been granted by this Court. Thus, as is clear from the subsection, this
Court’s jurisdiction
to grant leave itself is dependent on the Court a
quo having refused such leave. The proper procedure, as imperatively laid
down by section 20(4)(b), is for the would-be appellant to
apply for leave first
to the Court against whose judgment the appeal is to be made. If that Court
grants leave, then this Court may
entertain the appeal. If that Court refuses
leave, then (but only then) may this Court consider an application for leave to
appeal.
Thus section 20(4)(b) not only prescribes the proper procedure, but it
also defines the jurisdiction of this Court to entertain an
application for
leave to appeal.’
[23] In view of the considerable emphasis placed
by the respondents on this passage, some aspects should be emphasised about the
judgment.
The first is that the applicant for leave did not apply for leave from
the court of first instance and thus failed to take the first
step. (The same is
true of most, if not all, the cases where this court has said that an
application to the court a quo and its subsequent order are
jurisdictional facts.)[21] Second,
the judgment did not deal with the case where a litigant, following the correct
procedure, is unable to obtain a decision
from that court within a reasonable
time (relative to the circumstances). Third, the effect of the (interim)
Constitution on the
interpretation of the provision did not
arise.
[24] Although a ruling by the court below is a jurisdictional
fact, this does not mean that the filing of an appeal or an application
for
leave with this court is a nullity simply because the court below has not yet
given its ruling. That is apparent from a series
of judgments dating back to
Gabriel v Natal Law Society 1913 AD 327. There the appellant required
leave to appeal. The court below did not grant or refuse leave, wrongly
believing that it was unnecessary
to make a ruling. At the hearing the appellant
argued that leave was not required but this court disagreed. It then granted
leave
nunc pro tunc, as though proper application had been made
timeously, but warned that such procedure should not generally be
adopted.
[25] In terms of the then applicable statute, no interlocutory
order was subject to appeal save by leave of the court or judge making
the
order.[22] In other words, this
court could not grant leave, even if leave had been refused by the court of
first instance. The appellant in
Blaauwbosch Diamonds Ltd v Union Government
(Minister of Finance) 1915 AD 599 failed to apply for leave. Although this
court had no jurisdiction to hear the matter, it did not strike the appeal from
the roll
as being a nullity; instead it allowed the case to stand down to enable
the appellant to obtain the necessary leave. It did not hear
argument on the
merits and postpone the judgment pending the grant of leave because the court of
first instance was the final arbiter
of whether leave should be granted or not.
The hearing continued eleven days later, leave having been obtained in the
interim from
the court of first
instance.[23] The facts in Oliff
v Minnie 1952 (4) SA 369 (A) were virtually identical. The same provision
applied and the appellant failed to apply for leave to appeal from the court of
first instance. This court noted that it had no jurisdiction to dispose of the
case but nevertheless heard argument on the merits
and let the case stand over.
It said (at 376B-C):
‘This matter must, therefore, stand over to enable
the plaintiff to apply within twenty-one days of this judgment to the Court
a
quo for leave to appeal. If that Court grants such leave and the order
granting leave is lodged with the Registrar of this Court, we,
having heard
argument on the merits, will be in a position to deliver a judgment on the
merits and to make an appropriate order as
to costs. If the Court a quo
refuses leave to appeal and the order refusing such leave is lodged with the
Registrar of this Court, this matter will, without any
further order of this
Court, be deemed to have been struck off the roll with costs.’
The
reason for the ruling in the ultimate sentence was that, as mentioned, the court
of first instance could refuse leave, which would
put an end to the right of
appeal. The appeal was later upheld without further
argument.[24] A similar course was
taken in Sita v Olivier NO 1967 (2) SA 442 (A) 450E-H under a statutory
provision which, for all intents and purposes was identical to that contained in
s 20(4)(b) of the Supreme
Court
Act.[25]
[26] In
Gentiruco AG v Firestone SA (Pty) Ltd 1972 (1) SA 589 (A) 608E-G, Trollip
JA summed up the position when he said that –
‘Where the
necessary leave to appeal is lacking this Court may, in appropriate
circumstances, defer the hearing or determination
of the appeal to enable to
appellant to obtain such leave . .
.’[26]
It should be
emphasised that either the hearing or the determination (judgment) can be
deferred and, secondly, that the circumstances
should be appropriate before this
extraordinary procedure may be adopted.
[27] Instructive is Holt v
Brook 1959 (3) SA 803 (N). Under the applicable statute the appellant, in
order to appeal, had to give a prescribed notice (referred to as a s 61 notice)
to the other party of its intention to appeal and had to obtain the leave of the
court of first instance. In issue was the question
whether or not the notice
could precede the grant of leave. Broome JP, speaking on behalf of a full bench,
said (at 805C-F):
‘A litigant may surely form and notify an intention
to appeal before he has taken all the procedural steps which lie before
him.
These must be taken before his appeal can be heard, but the order in which they
are taken does not appear to me to be of any
importance, provided that each is
taken within the time, if any, specifically prescribed therefor. When a person
desires to institute
action in any Court he will invariably find that the law
prescribes an initial step which he must take to set his litigation on foot.
Usually it is a summons. Similarly a litigant against whom judgment has been
given who desires to appeal will find that an initial
step is laid down which he
must take to set his appeal on foot. Normally this step is the notice of appeal.
In the present case it
is the notice under sec. 61. When that notice is given
his appeal is on foot. It may be, as here, that he requires leave to appeal,
but
the obtaining of such leave is not the initial step which sets his appeal on
foot and without which there is no appeal on foot
at all. It is a step which he
must take before his appeal can be entertained by the Court of
Appeal.’
[28] In all the cases cited, the would-be appellant failed
to apply for leave to appeal from the court of first instance. Notwithstanding
the absence of this jurisdictional fact, this court accepted that it could hear
and decide the matter provided the condition was
fulfilled before judgment was
delivered. In this case the applicants are in a better position. They took all
the prescribed steps;
they did apply to the court below; they did apply to this
court. All that was missing was the ruling of the court below. That came
less
than 48 hours after conclusion of argument, but, as is apparent from the body of
authority cited, that is not fatal. The procedural
condition for the
determination of the applications for leave has now been
fulfilled.
[29] There is another reason why s 20(4)(b) of the Supreme
Court Act does not prevent a consideration of the application. All statutes
must
be read in the light of the Constitution. More particularly, s 39 enjoins
courts, when interpreting the Bill of Rights to promote
the values that underlie
an open and democratic society based on human dignity, equality and freedom; and
when interpreting any legislation,
to promote the spirit, purport and objects of
the Bill of Rights.
[30] Although the Constitution does not guarantee a
right of appeal in civil proceedings
explicitly,[27] a general right to a
‘fair’ hearing is entrenched in s
34.[28] Applied to the provisions of
the Supreme Court Act, this means that the proceedings there described must,
procedurally, be ‘fair’.
In Boodhoo & Ors v. Attorney General
of Trinidad and Tobago (Trinidad and Tobago) [2004] UKPC 17 (PC) the Privy
Council had to consider the effect of a basic right to ‘the protection of
the law’ contained in the constitution
of Trinidad and Tobago on a delay
in appeal proceedings, and it quoted with approval the following statement of
de la Bastide CJ
in the Court of Appeal of Trinidad and Tobago (at para
9):
‘It seems to me that this is the right that can most appropriately
be invoked by persons who complain of delay by a court in
delivering judgment or
for that matter failure to deliver judgment. Surely, if the protection of the
law means anything, it must
mean that persons are entitled to have recourse to
the appropriate court or tribunal prescribed by law for the purpose of enforcing
or defending their rights against others or resolving disputes of one kind or
another. It is axiomatic that such a right is meaningless
without a decision by
the court or tribunal to which the claim or dispute is referred for
adjudication.’
The Privy Council concluded by holding
that
‘delay in producing a judgment would be capable of depriving an
individual of his right to the protection of the law, as provided
for in section
4(b) of the Constitution of Trinidad and Tobago, but only in circumstances where
by reason thereof the judge could
no longer produce a proper judgment or the
parties were unable to obtain from the decision the benefit which they
should.’
(Para 12, emphasis added.) The same must apply to the
right to a ‘fair hearing’ in respect of an application for leave
to
appeal.[29]
[31] The Supreme
Court Act assumes that the judicial system will operate properly and that a
ruling of either aye or nay will follow
within a reasonable time. The Act
– not surprisingly – does not deal with the situation where there is
neither and a
party’s right to litigate further is frustrated or
obstructed. The failure of a lower court to give a ruling within a reasonable
time interferes with the process of this court and frustrates the right of an
applicant to apply to this court for leave. Inexplicable
inaction makes the
right to apply for leave from this court
illusory.[30] This court has a
constitutional duty to protect its processes and to ensure that parties, who in
principle have the right to approach
it, should not be prevented by an
unreasonable delay by a lower
court.[31] In appropriate
circumstances, where there is deliberate obstructionism on the part of a court
of first instance or sheer laxity or
unjustifiable or inexplicable inaction, or
some ulterior motive, this court may be compelled, in the spirit of the
Constitution and
the obligation to do justice, to entertain an application of
the kind presently before us.
[32] In Montsisi v Minister van
Polisie 1984 (1) SA 619 (A) the court dealt with s 32(1) of the since
repealed Police Act 7 of 1958. It proscribed the institution of legal
proceedings against
the police more than six months after the cause of action
had arisen. According to jurisprudence the six months period was a
‘vervaltermyn’,
which meant that it could not have been suspended
under the provisions of a prescription statute. The allegations were that the
appellant
had been detained by the SA Police on 10 June 1977 under the
provisions of the Terrorism Act 83 of 1976 and that he was assaulted
while in
detention on 13 June and 27 October 1977. He was only released from detention on
28 July 1978, after the lapse of the six
month period. It was common cause that,
by virtue of the provisions of s 6 of the Terrorism Act, the appellant was not
able to institute
any legal proceedings during the period of his detention. This
court found that his claim was not out of time applying the general
principle of
lex non cogit ad impossibilia (at 635A-H). This principle, which is
really one of the law of contract, has general application. Applied to the
issues in this case,
if an applicant finds it impossible to obtain a ruling
within a reasonable period from a court below, its absence cannot be held
against it. (By parity of reasoning one could apply the principle of fictional
fulfilment of a condition.)
[33] That brings me to a consideration of
whether, on the facts of this case, there was an undue delay in issuing a
ruling, which
entitled the applicants to approach this court for leave. In this
regard it is well to remember that by its very nature the judicial
process is
slow, judges have other cases to attend to, they have to consider their verdicts
and give reasoned judgments, due allowance
must be made for the speed with which
individual judges work, and that –
‘citizens who are engaged in
litigation have to face a number of possible hazards. The members of a court
consisting of an even
number of judges may divide evenly, so giving rise to the
need for a rehearing. A jury may have to be discharged or a judge to recuse
himself at an advanced stage of a trial, without anyone having been at fault. A
judge may die or take ill before concluding the hearing
of a case or before
judgment is given. These constitute the ordinary risks inseparable from
litigation . .
..’[32]
[34] The
present matters began as urgent applications and, since the parties were agreed
that they were urgent, the court below
properly dealt with them on that basis.
Two compendious judgments (in all about 180 typed pages) were delivered within
two months.
The applications for leave raised no new points that had to be
covered by any further judgment. Applications for leave are ordinarily
dealt
with by courts expeditiously and leave is either granted or refused instantly,
sometimes accompanied by an ex tempore judgment of a page or
two.[33] The validity of
regulations that have a profound effect on many would usually provide compelling
reasons to have the issue determined
as soon as
possible.[34]
[35] The
respondents did not submit that the delay was reasonable or justifiable. Their
counsel was not prepared to deal with the
question of what the case would have
been if a court refuses because of an ulterior motive to give a ruling, saying
it was hypothetical.
Instead, he submitted that the court all along intended to
deliver a ruling, relying on the meeting with the judge president on 12
November. It really misses the point. One is supposed to adjudge the matter as
it stood when the applications were filed, and objectively.
[36] It is
necessary to have regard to the terms of Hlophe JP’s judgment to see
whether it contains any clues as to why it
had to be delayed. The first seven
pages of the judgment deal with the reason why the application for leave was not
dealt with in
chambers but in open court. Those reasons are academic and have
nothing to do with the question whether or not leave should have
been granted.
During the course of this discussion Hlophe JP took umbrage to the
applicants’ direct approach to the head of
this court to determine the
availability of dates before the application had been determined, as if it
amounted to some kind of
lese-majesty.[35] Apparently he did
not appreciate fully that the applicants were entitled to approach this court
either by way of an appeal or an
application for leave to appeal, irrespective
of the outcome of their applications before the court below.
[37] Hlophe
JP, when dealing with the merits of the application, himself said that
–
‘there was absolutely nothing new that came out in argument
when we heard the application for leave to appeal. All the issues
raised were
fully canvassed in a long judgment which was carefully written.’
Why
then, one may fairly ask, did it take longer to dispose of the application for
leave than the application itself? He said that
the fact that there was a
minority judgment did not mean that another court might reasonably agree with
the minority. (As Antoine
de Saint-Exupéry said, it is harder to judge
oneself – and, one may add, the fruits of one’s labours – than
to judge others.) He proceeded to find (so it would appear) that since the case
raises constitutional issues, leave to this court
should not be granted,
apparently assuming that a court of first instance does have the right to choose
the appeal forum while all
it can decide is whether there were reasonable
prospects of success.
[38] Ineluctably, in the light of the nature and
scope of the issues, the period of the delay, the lack of explanation, the
urgency
of the case, the content of Hlophe JP’s judgment and the other
factors mentioned, the only conclusion can be that the delay
was not only
regrettable, it was unreasonable – so unreasonable in fact that it could
only be interpreted as a refusal of leave.
[39] The judgment of Hlophe JP
concluded with a reference to the spirit of ubuntu in interpreting
statutes. The word appeared in an endnote of the interim Constitution where it
dealt with national unity and reconciliation:
‘These can now be
addressed on the basis that there is a need for understanding but not for
vengeance, a need for reparation
but not for retaliation, a need for
ubuntu but not for victimisation.’
It does, however, not appear
in the Constitution in express terms. Ubuntu has many dimensions but its
application to statutory interpretation is
novel.[36] It ought to apply to the
relationship between courts and the respect required of organs of state and
courts towards citizens and
towards each other. One does sense that the court
below was irritated because the applicants had the temerity to ask for a quick
disposition of the applications for leave. There are some who believe that
requests for ‘hurried justice’ should not
only be met with judicial
displeasure and castigation but the severest censure and that any demand for
quick rendition of reserved
judgments is tantamount to interference with the
independence of judicial office and disrespect for the judge
concerned.[37] They are seriously
mistaken on both counts. First, parties are entitled to enquire about the
progress of their cases and, if they
do not receive an answer or if the answer
is unsatisfactory, they are entitled to
complain.[38] The judicial cloak is
not an impregnable shield providing immunity against criticism or reproach.
Delays are frustrating and disillusioning
and create the impression that judges
are imperious. Secondly, it is judicial delay rather than complaints about it
that is a threat
to judicial independence because delays destroy the public
confidence in the judiciary. There rests an ethical duty on judges to
give
judgment or any ruling in a case promptly and without undue delay and litigants
are entitled to judgment as soon as reasonably
possible.[39] Otherwise the most
quoted legal aphorism, namely that ‘justice delayed is justice
denied’, will become a mere platitude.
Lord Carswell recently
said:
‘The law's delays have been the subject of complaint from
litigants for many centuries, and it behoves all courts to make proper
efforts
to ensure that the quality of justice is not adversely affected by delay in
dealing with the cases which are brought before
them, whether in bringing them
on for hearing or in issuing decisions when they have been
heard.’[40]
In Goose v
Wilson Sandford and Co[41] the
Court of Appeal censured a judge for his delay in delivering a reserved judgment
and said:
‘Compelling parties to await judgment for an indefinitely
extended period . . . weakened public confidence in the whole judicial
process.
Left unchecked it would be ultimately subversive of the rule of
law.’
THE MERITS
[40] In order to succeed, the
applicants have to persuade us that there is a reasonable prospect of success in
the appeal. Once an
application of this kind is referred to oral argument there
is no reason to have two hearings, one to ascertain whether there are
reasonable
prospects and a second to determine the merits of the appeal. The respondents,
forewarned that this established procedure
may be followed, decided, as
mentioned, not to address these
issues.[42] Although we have been
deprived of the privilege of their argument, we are fortunate to have a full
judgment of the majority of the
court below which dealt favourably with most of
the points raised by the respondents in their papers. One can also glean from
the
affidavits, which contain much by way of argument, and the minority judgment
what the respondents’ contentions would have been.
Cowed by the
respondents’ refusal to be of any assistance we cannot be. Organs of
state, who have a constitutional duty to,
inter alia, assist courts to
ensure their effectiveness,[43] have
always treated courts with respect and we assume that the refusal to argue is
not indicative of a change of heart but rather
of inappropriate legal advice
based on overconfidence.
LEGALITY
[41] In Gerber v MEC of
the Gauteng Provincial Government, Development Planning & Local Government
[2002] 4 All SA 518, 2003 (2) SA 244 (SCA) at para 35 it was pointed out that
–
‘The Republic of South Africa is a constitutional State. Local
authorities and other State institutions may act only in accordance
with powers
conferred on them by law. This is the principle of legality, an incident of the
rule of law.’
This brings me to the main thrust of the attack on the
validity of the regulations, which is that they lack legality or, in
pre-Constitutional
parlance, that they are ultra vires. As was said by
Chaskalson P,
‘What would have been ultra vires under the common
law by reason of a functionary exceeding a statutory power is invalid under the
Constitution according to the doctrine
of legality. In this respect, at least,
constitutional law and common law are intertwined and there can be no difference
between
them.’[44]
The
learned President further pointed out that the doctrine of legality, as an
incident of the rule of law, was an implied provision
of the interim
Constitution; that it is central to the conception of our constitutional order
that the legislature and executive
in every sphere are constrained by the
principle that they may exercise no power and perform no function beyond that
conferred upon
them by law; and that the Constitution in specific terms now
declares that the rule of law is one of its foundational
values.[45] In this regard it is
well to remember that it is not the function of the judiciary
‘to
“second guess” the executive or legislative branches of government
or interfere with affairs that are properly
their concern’
but that
‘[a]dherence to the prescribed forms and procedures and insistence
upon the executive not exceeding its powers are important
safeguards in the
Constitution’[46]
and that
questions of legality cannot be decided on the basis that the minister or the
committee acted in good faith.[47]
[42] In order to determine the scope of the minister’s powers in
promulgating the regulations in contention the logical starting
point is an
interpretation of the Medicines Act. The Act must be read in the light of s
27(1) of the Bill of Rights, which provides
that everyone has the right to have
access to health care services, including reproductive health care and that the
state must take
reasonable legislative and other measures, within its available
resources, to achieve the progressive realisation of this right.
One has to
agree that the right of access to health care includes the right of access to
medicines although this right is not without
limitations.[48] It is also correct
that the prohibitive pricing of medicines may be tantamount to a denial of the
right of access to health care.
All that is really common cause. What is not, is
how parliament has sought to achieve the progressive realisation of this right
through
the provisions of the Act.
[43] There is another dimension of the
right in issue, namely the negative obligation resting on the state to desist
from preventing
or impairing the right of access to health care
services.[49]
[44] As
initially promulgated, the Medicines Act was called the Drugs Act and provided
for the registration of drugs for human use,
the establishment of a Drugs
Control Council and matters incidental thereto. It has been the subject of
repeated amendments, including
one in 1974 when a name change to the Medicines
and Related Substances Control Act took
place.[50] The word
‘control’ was removed from the name by s 28 of the Medicines and
Related Substances Control Amendment Act 90
of 1997. When courts have
said[51] that the purpose of the
Medicines Act was directed at the control of medicines and so-called related
substances, to regulate the
manner in which scheduled substances were made
available to members of the public, to control the quality and supply of
medicines
generally and to protect the citizenry at large, they were not dealing
with the provisions introduced by the amending Act. Some are
of particular
significance to this case, namely sections 15C, 18A, 18B and 22G. In order to
determine the purpose and meaning of
the provisions introduced by amending Act
one has to delve deeper.
[45] It needs to be mentioned in parenthesis
that the Medicines Act was supposed to have been repealed – save for some
provisions
including those just mentioned – by the South African Medicines
and Medical Devices Regulatory Authority Act 132 of 1998. Because
of certain
problems, the promulgation by the President of this Act was set
aside.[52] Since then the repealing
Act itself has been
repealed.[53]
[46] The
Medicines Act has no preamble and its long title is singularly uninformative. It
provides for the registration of medicines
and states that only registered
medicines may be sold (s 14(1)). They, and related
substances,[54] are classified. In
general terms, schedule 0 drugs may be sold in an open shop; schedule 1 drugs
may by sold by pharmacists without
a prescription; schedule 2 drugs may also be
sold by pharmacists without a prescription but only under stricter conditions;
schedule
3, 4, 5 and 6 substances may be sold by a pharmacist but only with a
prescription; whereas schedule 7 and 8 substances are prohibited
substances (s
22A). Persons other than pharmacists who are registered under the Health
Professions Act 56 of 1974 may be licensed
to dispense medicines (s 22C(1)(a)).
The Act also recognises the existence of a chain of supply for medicines, and
manufacturers,
importers, wholesalers and distributors must all be licensed (s
22C(1)(b), s 22H). It follows from this that dispensers of pharmaceuticals
are
considered essential to the provision of medicines to the public, especially
since the number of dispensing doctors is subject
to regulation (s 22C(1)(a)).
It also follows that the viability of the dispensing profession is a matter of
public interest and was
a matter of concern to the legislature. I shall deal in
more detail with this aspect later.
[47] It is common cause that s 22G
is concerned with the provision of more affordable medicines. There are hardly
any contextual
guidelines available to determine its meaning. (In due course I
shall refer to its history because that throws some light on its
scope.) One
contextual pointer, however, is s 15C, which provides that the minister may
prescribe conditions for the
‘supply of more affordable medicines in
certain conditions for the supply of more affordable medicines to protect the
health
of the public’.
The ‘conditions’ are carefully
circumscribed: they deal with parallel importation of patented medicines and the
importation
of medicines identical to others already registered, ie, to obviate
or limit the registration procedures for new suppliers of medicines
already on
the market. The present regulations, it needs to be emphasised, do not purport
to and could not have been promulgated
under this section.
[48] Instead
the regulations were, as mentioned, made under s 22G, which in its present form
provides as follows:
‘22G ‘Pricing
committee.—(1) The Minister shall appoint, for a period not
exceeding five years, such
persons as he or she may deem fit to be members of a
committee to be known as the pricing committee.
(2) The Minister
may, on the recommendation of the pricing committee, make
regulations—
(a) on the introduction of a transparent pricing system
for all medicines and Scheduled substances sold in the Republic;
(b) on an
appropriate dispensing fee to be charged by a pharmacist or by a person licensed
in terms of section 22C (1) (a);
(c) on an appropriate fee to be
charged by wholesalers or distributors or any other person selling Schedule O
medicines.
(3) (a) The transparent pricing system
contemplated in subsection (2) (a) shall include a single exit price
which
shall be published as prescribed, and such price shall be the only price at
which manufacturers shall sell medicines and Scheduled
substances to any person
other than the State.
(b) No pharmacist or person licensed in
terms of section 22C (1) (a) or a wholesaler or distributor shall sell a
medicine
at a price higher than the price contemplated in paragraph
(a).
(c) Paragraph (b) shall not be construed as preventing a
pharmacist or person licensed in terms of this Act to charge a
dispensing fee as
contemplated in subsection (2) (b).
(4) To the members of the
pricing committee who are not in the full-time employment of the State may be
paid such remuneration
and allowances as the Minister, with the concurrence of
the Minister of Finance, may determine.’
[49] It is clear that the
minister’s powers to make regulations is dependent on the recommendation
of the pricing committee,
in other words, such a recommendation is a
jurisdictional fact. The committee’s recommendation has to be in
accordance with
the provisions of s 22G – ie it must be a lawful
administrative action as provided for by s 33(1) of the Constitution –
since the committee has no power beyond that given to it by this section. And it
follows from the principle of legality that the
minister cannot accept a
recommendation or promulgate a regulation that does not fall squarely within the
section.
TRANSPARENT PRICING SYSTEM
[50] Section 22G
permits regulations that introduce a ‘transparent pricing system’.
The concept is not defined and must
therefore be given its ordinary meaning
unless there are reasons for not doing so. The only qualifier for the pricing
system is that
it must be ‘transparent’, ie, open to public
scrutiny. This is explained further in para (3)(a), which provides that
the
system must include a single exit price that has to be published in a prescribed
manner.
[51] Some aspects need to be emphasised:
(a) The ‘single exit price’ is the price charged by the ‘manufacturer’. (b) The manufacturer may sell at that price only to persons other than the state. (c) The Act itself draws a clear distinction between a ‘manufacturer’, an ‘importer’, a ‘wholesaler’ and a ‘distributor’. (d) An importer, wholesaler or distributor may not sell medicines at a price higher than the manufacturer’s single exit price. (e) The only exception may be schedule 0 medicines: wholesalers, distributors and other vendors may charge a prescribed ‘appropriate’ fee in addition to the manufacturer’s single exit price. (f) A dispenser may also not sell at a higher price than the manufacturer’s exit price. (g) However, a dispenser may charge a prescribed ‘appropriate dispensing fee’. (h) These provisions must be read in the light of s 18A and 18B: section 18A prohibits the supply of medicines according to a bonus system, rebate system or other incentive system while s 18B prohibits the supply of free samples.
[52] The
Act, in this form, must have raised immediate problems for the committee. The
first would have been that it does not take
account of the fact that
manufacturers of medicines may be foreign concerns and that their products may
be imported by third parties.
(As mentioned, the Act requires importers to be
licensed.) The committee, one assumes, recognised the problem of prescribing to
foreign
manufacturers that they have to publish a single exit price and that
they may not sell for more than that price. The committee was
also faced with
the problem that it could hardly be fair to deny importers the right to charge
more than the manufacturer’s
price. No doubt, in order to overcome these
defects in the Act, the committee’s proposal was to recognise that an
‘importer’[55] purchases
medicines from a manufacturer abroad and to define the single exit price as the
price not only set by the manufacturer,
but, alternatively, by the
importer.[56] This could not be
done. The Act is clear. It requires manufacturers (and only manufacturers) to
set their single exit prices, and
importers are a genus different from
manufacturers and cannot by any stretch of the imagination be equated with them.
It follows
that, to this extent, the regulations are ultra vires the Act:
the committee was not entitled to make the proposal and the minister was not
entitled to accept it.
[53] An associated problem the committee obviously
had was that the Act does not allow wholesalers or distributors to charge more
than the manufacturer’s single exit price. However, the Act does not
prohibit wholesaling or distributing by third parties
(because that would have
amounted to a breach of the constitutional obligation not to make medicines
inaccessible) and since it requires
them to be licensed, one has to accept that
the Act regards them as a link in the supply chain. The only limitation the Act
places
on wholesalers is to oblige them to purchase from the original
manufacturer or the primary importer of the finished product (s 22H).
[54] In order to solve the problem the committee devised the idea of a
logistics fee, which is payable in respect of ‘logistical
services’.
These are defined to mean –
‘those services provided by
distributors and wholesalers in relation to a medicine or Scheduled substance
including but not
limited to warehousing, inventory or stock control management,
order and batch order processing, delivery, batching, tracking and
tracing, cold
chain storage and distribution.’
The manufacturer or the importer has
to agree with the wholesaler or distributor on this fee. The regulations define
the single exit
price as ‘the price set by the manufacturer or importer .
. . combined with the logistics fee’, which is something greater
than the
manufacturer’s price, since it includes both the manufacturer’s
price and the logistics fee.
[55] All this, with the best of motives,
circumvents s 22G which states expressly that the ‘single exit
price’ is the
manufacturer’s selling price. Wholesalers, as the Act
and the regulations recognise, purchase from manufacturers or
importers.[57] To deem their mark-up
as part of the manufacturer’s price is an impermissible
simulation.[58]
[56] There
is another problem that goes to the root of this regulation. Providing for a
‘transparent’ pricing system was
the whole object of the exercise.
The Act says so in terms but the logistics fee is not transparent precisely
because it is a fee
negotiated privately between the manufacturer and
wholesaler. Although the minister may prescribe a maximum (probably
impermissibly,
as an improper delegation), that in itself does not make the fee
transparent.
[57] Next to consider is whether s 22G permits, through the
pricing system, price control by the state and, if not, whether the regulations
provide for price control. As Yekiso J correctly pointed out, the legislative
history of the enactment shows that its purpose is
‘the elimination of
the system of discounts and subsequent mark-ups which had the effect of
rendering medicine unaffordable,
particularly to the poor section of our
population’
because
‘the discounting and the subsequent
marking-up of pharmaceutical products that characterised the sale of such
products in the
past, had the effect of negating the right to healthcare
enshrined in section 27(1) of the Constitution.’
Therefore
–
‘Section 22G was enacted to address the mischief of the system
of discounting and the subsequent marking-up of pharmaceutical
products in
circumstances where it was not known how the price, which the end user or
consumer or patient had to pay, was arrived
at.’
[58] In other
words, since manufacturers are obliged to sell to all and sundry at a single
exit price that is transparent and may
not give discounts, the public will be
able to know what the true price of the goods are. And since dispensers are only
entitled
to add a prescribed fee, a member of the public would be able to assess
whether the price paid is the correct one. Because manufacturers
would know what
the prices charged by their competitors are, they will have to reduce their
prices and publish the reduced prices
in order to compete.
[59] That is
the price reduction mechanism envisaged by the section. It does not contemplate
a system whereby the committee, the state
or the regulations can fix or limit
the manufacturer’s exit price. Although this is clear from the section as
a whole it is
comforting to know that the
department[59] agreed with this
interpretation as did the court
below[60] although the second
respondent did not in her affidavit.
[60] The majority found that
‘the State does not play a role in the determination of the single exit
price.’ The problem
with this finding is that it was made without any
regard to the specifics of the regulations. Although reg 5(1) provides that the
manufacturer must set the single exit price upon the commencement of the
regulations, reg 5(2) immediately set a cap on that price:
it could have been no
more than a price calculated with reference to a formula based on prices that
prevailed during the year 2003.
It becomes more intricate when the regulations
deal with new medicines. Then the price of the medicine must be calculated
–
‘using the average of the total rand value of sales less the
total rand value of the discounts for the period for which the
medicine was sold
and with reference to the price of that medicine in other countries in which
prices of medicines and Scheduled
substances are regulated and
published.’[61]
(The other
countries are not specified, but that is a discrete problem.)
[61] The
next phase is the determination and publication by the director-general of
–
‘a methodology for conforming with international benchmarks,
taking into account the price, and factors that influence price,
at which the
medicine or Scheduled substance, or a medicine or Scheduled substance that is
deemed equivalent by the Director-General,
is sold in other countries in which
the prices of medicines and Scheduled substances are regulated and
published’.[62]
Within
three months thereafter the single exit price must –
‘conform
with international benchmarks in accordance with such
methodology.’[63]
[62] Finally,
for a period of one year the single exit price may not be increased; it may not
be increased more than once a year and
the extent to which it may be increased
is to be determined by the minister after consultation with the
committee.[64]
[63] In the
light of this elementary analysis of the pricing system contained in the
regulations it is impossible to subscribe to
the finding of Yekiso J that
‘the applicants’ concern as regards the Regulations complained
of, namely, that they restrict the manufacturers’
and the importers’
right to determine a single exit price, has no
merit.’[65]
While the Act
contemplates the imposition of a downward pressure on the prices of medicines
through the introduction of a transparent
pricing system, the committee thought
that it contemplates direct price control. In its submission to the minister,
which accompanied
the draft regulations, it explained that ‘the regulation
of medicine prices is both justifiable and necessary’ and proceeded
to set
out how manufacturers’ prices would be ‘reduced’ and
‘managed’ in the way set out above. Yekiso
J quoted a number of
extracts from the minutes of the committee which are consistent with the
contents of the memorandum. He found,
however, that these references were
selective and that, having regard to the record as a whole, the inference that
the committee
had regard to irrelevant considerations was unjustified.
Unfortunately, he did not provide any references from which a contrary
conclusion
can be drawn and I could not find any. Whether the regulation of
medicine prices is justifiable or necessary and how it should be
done are
matters for parliament to decide. It chose the limited option contained in s
15C. It was not for the committee to pursue
its own agenda, irrespective of how
commendable its motives may have been, and the minister was not entitled to
accept a recommendation
that did not fall within the parameters of the
Act.[66] In a country struggling
with limited resources to meet the needs of the poor it is laudable and noble to
strive to reduce the costs
of medicines. We are, however, a nation that
subscribes to the primacy of the rule of law and all measure to that end must
comply
the principle of legality.
[64] Another problem with the
regulations in this regard is the fact that while the Act requires that the
regulations should prescribe
the method of publication of the single exit price,
the regulations have delegated the function to the
director-general.[67] This the Act
does not permit.
[65] The regulations, insofar as they deal with a
transparent pricing system, consequently fail the legality test on many
fundamental
aspects.
SCHEDULE 0 MEDICINES
[66] It is
convenient to deal now with the regulations where they purport to prescribe, in
the words of s 22G
‘an appropriate fee to be charged by wholesalers or
distributors or by any other person selling Schedule 0
medicines.’[68]
It will be
recalled that sch 0 medicines are those that can be sold in an open
shop.
[67] There is once again a problem with the Act. While it allows
for the setting of fees to be charged by vendors of sch 0 medicines,
it
simultaneously prohibits the sale of sch 0 medicines at a price higher than the
single exit price. The only add-on permitted is
the fee of the dispenser and,
unless one indulges in hermeneutical gymnastics, the fee of the wholesaler or
distributor, though prescribed,
cannot be added to the ‘single exit
price’. But that has nothing to do with the validity of the regulations
and I shall
approach the matter on the basis that there is no prohibition on the
addition of the fee to the single exit price.
[68] In its final
recommendation to the minister, the committee noted that in its view substantial
competition prevails in the sch
0 market. It therefore recommended that all
retailers be allowed to sell these medicines with a percentage mark-up as they
have done
in the past, save that the mark-up may not exceed what it was at the
time of the introduction of the regulations. Regulation 13 accordingly
provides:
‘The appropriate fee to be charged by any person, other than
a wholesaler or distributor, in respect of Schedule 0 medicines
shall not exceed
the percentage mark-up in respect of that medicine or Scheduled substance that
was applied at the date of commencement
of these
regulations.’
[69] Because sch 0 medicines are subject to a single
exit price and that price does not allow for any mark-up or fee for wholesalers
or distributors, by excluding them from reg 13, the regulation in effect
determines that wholesalers and distributors are not entitled
to any fee, let
alone an appropriate fee.
[70] The mark-up of each individual retailer
on each individual product, which it had on the shelf on 2 May, cannot be
considered
to be a ‘fee’. A ‘fee’ is in ordinary
parlance a payment made to a professional or para-professional in exchange
for
advice or services. It is not the same as a gross profit or a mark-up on goods.
There must in the light of the regulations be
tens of thousands of
‘fees’ in the market place. The Act insists that the
‘fee’ must be ‘appropriate’.
There is no basis for the
assumption that the mark-up on a particular medicine on a particular day by a
particular retailer can ever
amount to an appropriate fee. For instance, the
item could have been sold as a loss leader on the relevant date, in which event
the
product must be sold at a loss in perpetuity. On the other side of the coin,
if the item was then sold at an excessive price, the
retailer will be able to
carry on selling at that price.
[71] The regulations, insofar as they
deal with sch 0 medicines, once again do not pass muster. Yekiso J, while
holding the contrary
gave no reasons for his conclusions – except that
retailers would have known what their mark-ups were – and did not deal
with the issues raised in the preceding paragraphs.
‘APPROPRIATE
DISPENSING FEE’
[72] While s 22G permits the minister, on the
recommendation of the committee, to make regulations on an ‘appropriate
dispensing
fee’ to be charged by a pharmacist or a person licensed in
terms of section 22C(1)(a), the Pharmacy Act 53 of 1974 (in s 49(1)(a))
allows
the minister, in consultation with the Pharmacy Council, to make regulations
relating to
‘the practice of pharmacy, the conduct of the business of
a pharmacist, the tariff of fees payable to a pharmacist in respect
of
professional services rendered by him and the trading activities of a
pharmacist’.
[73] This apparent contradiction gave rise to
different interpretations in the court below. Traverso DJP sought to solve the
problem
by holding that s 22G did not permit the making of regulations that fix
professional fees but only to prohibit the giving of rebates
on dispensing fees
or require their publication by pharmacists. I cannot agree because the attempt
to harmonise the two provisions
appears to me to be forced. The correct way to
approach the matter is to consider that s 22G is a narrow provision while s
49(1)(a)
is a general provision. The general provision must yield to the
specific. Consequently, the minister may make regulations relating
to the
quantum of dispensing fees under s 22G and under the Pharmacy Act the tariff of
all other fees, excepting dispensing fees, may be prescribed. If no regulations
are made under s 22G, dispensing fees may be set under the Pharmacy
Act.
[74] The Medicines Act, in requiring dispensing fees, gives
recognition to the fact that dispensers are first and foremost professionals
and
not traders in medicines. Although the advisability of the new scheme was
debated at some length by some deponents, this is not
open to question because
parliament has made a policy decision in this regard and the constitutionality
of s 22G is not in issue.
Even though dispensers perform a professional
function, their fee cannot be based on a simple time-related basis because, in
order
to provide their service they have to incur business related operating
costs like labour, stock management, capital costs, the financing
of stock and
debtors (including medical aid schemes) and the like. Hospital pharmacies, for
instance, are required by law to have
certain medicines in stock and, while the
average pharmacy may keep 2000 stock items, they generally stock between 10 000
and 12
000 line items.
[75] The next issue is the justiciability of the
regulations in relation to the quantum of the dispensing fees. The section
requires
the dispensing fee to be ‘appropriate’. What is appropriate
was not left to the discretion of the minister, and also
not to that of the
committee. In this regard there is a clear break from the approach adopted in
matters such as security legislation
during the pre-Constitutional era. There,
the jurisdictional fact was quite often the opinion of one or other functionary
and, provided
the functionary held the opinion, courts were rather hamstrung.
Here the jurisdictional fact is not someone’s opinion but an
objective
fact, namely a dispensing fee that must be ‘appropriate’. Whether it
is appropriate, can be tested judicially.
If the fee does not pass this
threshold requirement, the regulation is pro tanto void because it has no
legal basis or
justification.[69]
[76] The
word ‘appropriate’ means ‘specially suitable’ or
‘proper’.[70] In
Hoffmann v South African Airways 2000 (11) BCLR 1211; 2001 (1) SA 1 (CC)
paras 42-43 the court had to determine its meaning in the context of
‘appropriate relief’ as contemplated by section
38 of the
Constitution. Ngcobo J said that
‘“appropriate relief” must
be construed purposively, and in the light of section 172(1)(b), which empowers
the Court,
in constitutional matters, to make “any order that is just and
equitable.” Thus construed, appropriate relief must be
fair and just in
the circumstances of the particular case. Indeed, it can hardly be said that
relief that is unfair or unjust is
appropriate. As Ackermann J remarked, in the
context of a comparable provision in the interim Constitution, “[i]t can
hardly
be argued, in my view, that relief which was unjust to others could,
where other available relief meeting the complainant’s
needs did not
suffer from this defect, be classified as appropriate.” Appropriateness,
therefore, in the context of our Constitution,
imports the elements of justice
and fairness.’
‘Fairness requires a consideration of the
interests of all those who might be affected by the order. In the context of
employment,
this will require a consideration not only of the interests of the
prospective employee but also the interests of the
employer.’
[77] In the present context, I believe, the word has a
similar connotation. It can hardly be argued that a dispensing fee, which is
unjust or unfair, can be ‘appropriate’. One has to assume that the
legislature did not intend unjust or unfair fees.
In determining what is
appropriate one must consider the conflicting interests of all those involved
and affected. On the one hand
there is the public, which is entitled to access
to health care including affordable medicines. On the other hand there are the
interests
of dispensers who, in terms of the Act, are essential to the public
for the supply of medicines and whose economic viability is implicitly
recognised by the Act and is of national importance. As the minister herself
once said:
‘The pharmacy profession with its various specialities is a
crucial role-player in this regard. It embodies the knowledge spectrum
of
formulating, manufacturing, quality control, efficacy, safety, appropriate
usage, and drug supply management of drug
products.’[71]
One is
really dealing with the balancing act implicit in the right of access which, as
mentioned, encompasses positive and negative
obligations on the state.
Affordability is not the only dimension; access is just as important. Cheap
medicines available at two
hypermarkets provide cold comfort to the poor living
in a township or on the platteland. This means that, in order to be appropriate,
the fee must be such that affordable medicines do not become
inaccessible.
[78] To avoid any misapprehension about the scope of s 22G,
it must be emphasised that it deals with the private sector only. Medicines
sold
to the state or dispensed by the state are excluded from its operation. Those
who are dependent on the state for access to health
care receive no benefit from
the regulations, nor does the
state.[72]
[79] There is not
an absolute standard for being appropriate and more than one fee can be
appropriate. The word carries with it a
measure of elasticity and reasonable
persons may within reason disagree on what is and what is not appropriate. A fee
structure may,
for instance, be appropriate within the meaning of s 22G even if
it leads to the closure of some pharmacies because the prescribed
fee need not
keep all pharmacies afloat or provide all pharmacists with gainful employment.
The fee, also, should not cross-subsidise
the unprofitable parts of a
pharmacist’s business. But the fee should not be such that only a few
large dispensers located
in relatively affluent areas with huge turnovers can
survive.
[80] The Act does not define ‘dispensing’.
Ordinarily it means to make up medicine or to supply it according to a
doctor’s
prescription. In this case the question arose whether it included
formulation or compounding and whether a dispenser is entitled
to charge, under
the Act, additionally for compounding. It arose in the context of the
appropriateness of a fee of R104,00 for reconstituting
and preparing a set of
chemotherapy drugs, which may take an hour and a half to prepare, which requires
special equipment and procedures,
and where the cost to the pharmacist of the
medicines amounts to R2 146,62 or, in another instance, a fee of R26,00 for
compounding,
taking two and a half hours, of medicine costing R8 715,00. In the
answering affidavits the respondents attempted to justify the
fee by stating
that compounding can be charged for separately. The deponent on behalf of the
minister (who was a member of the committee)
and the second respondent (its
chair) were not in agreement as to exactly what can be charged extra. But all
that is really of no
consequence. Section 22G is clear. It prohibits any add-ons
except the prescribed dispensing fee. Whatever one understands under
the term,
it is all that can be added to the single exit price. Any other interpretation
would defeat the object of the Act. This
illustrates that the committee
misunderstood the Act and that impacts materially on whether the prescribed fee
is indeed appropriate.
[81] The fee prescribed to be charged by
pharmacists has to be calculated as follows (reg 10):
‘(1) With regard
to medicines and scheduled substances falling into Schedules 1 and 2 of the Act,
in the absence of a prescription
the dispensing fee, exclusive of VAT, must not
exceed—
(a) 16% of the single exit price of a medicine or Scheduled
substance where the single exit price of that medicine or Scheduled substance
is
less than one hundred rands;
(b) sixteen rands in respect of a medicine or
Scheduled substance where the single exit price of that medicine or Scheduled
substance
is greater than or equal to one hundred rands.
(2) With regard to
medicines and scheduled substances falling into Schedules 3, 4, 5, 6, 7, and 8
of the Act, and medicines and Scheduled
substances falling into Schedules 1 and
2 of the Act in respect of which a prescription has been written, the dispensing
fee, exclusive
of VAT, must not exceed—
(a) 26% of the single exit
price in respect of a medicine or Scheduled substance where the single exit
price of that medicine or
Scheduled substance is less than one hundred
rands;
(b) twenty six rands in respect of a medicine or Scheduled substance
where the single exit price of that medicine or Scheduled substance
is greater
than or equal to one hundred rands.’
[82] The simplest way of
determining whether these figures, which appear to have been calculated since
they are not round figures,
represent fees that are appropriate would have been
to have regard to the record of the committee’s meetings or to the
respondents’
evidence as to how they were calculated. Except for a general
statement that all factors were taken into account, there is no evidence
or
document that shows what those factors were, what weight they bore, whether any
calculations were made and, more particularly,
whether any regard was given to
the viability of the dispensing
profession.[73] Yekiso J surmised
that the committee’s recommendation ‘was obviously preceded by some
factual background’ but if
it were, the committee’s deafening
silence is not understood. Assuming that it took, in the learned judge’s
words, ‘a
conscious decision’ that these fees are
‘appropriate’ (of which there is no evidence) that is of no
assistance
in the absence of an explanation as to how or why it took the
decision.
[83] Bereft of an explanation from those in the know, it is
necessary to deal with the expert evidence filed by the applicants. Dr
Robert
Stillman, a highly qualified economist, who runs an international consultancy
specialising in the economics of competition
policy and regulation called
Lexecon, did a financial analysis to assess the likely impact of these fees on
the future economic viability
of different segments of the pharmacy profession.
He concluded that the fees will not provide pharmacists in any of the sectors
analysed
with sufficient revenues to cover their operating costs.
[84] His conclusion was based on a careful and detailed analysis of
factual data and cannot be dismissed as ‘sheer speculation’
as
Yekiso J did without any analysis of the facts. There is a difference between
speculation on the one hand and prediction on the
other. Stillman took as his
starting point the actual figures of a number of pharmacies for April 2004. He
recalculated their operating
profit or loss on the assumption that the
regulations had been in force during that month. For example, in relation to
courier pharmacies,
which provide an indispensable service to those who are
bedridden or housebound, he analysed the operations of one of the three largest
companies, CMD, and concluded that for the month tested, its gross profit margin
would have been reduced by 37% which would have
eliminated its operating profits
and would have left it with an operating loss equal to 5,1% of
sales.[74] He did a similar exercise
in relation to the New Clicks pharmacies, which are community pharmacies, and
found that the operating
profit margins would have been negative in 67 of the 69
stores covered. His analysis of the impact on pharmacies in medical centres
was
that they would have suffered an operating loss equal to 20% of revenue.
Hospital pharmacies would have suffered an operating
loss of 8,7% of revenue.
[85] Mr Willem Jordaan, a pharmacist with a master’s degree in
pharmaceutical economics, did a detailed exercise in relation
to the New Clicks
pharmacies. In this he excised the front shop activities in order to isolate the
effect of the fees on the dispensing
business and to exclude the effect of
cross-subsidisation. He calculated the net loss per line item to be
R5,33.
[86] The answer on behalf of the first respondent was one of a
denial which was to be demonstrated by expert evidence. Prof Mooney,
an
Australian expert, gave an exposition why the free market system does not work
for pharmaceuticals and why regulation is required,
none of which was ultimately
helpful in determining the answers to the questions before us. Mr Pillay, the
director of pharmaceutical
economic development in the department, who one would
have expected knew how the fees were calculated, limited his evidence to the
question whether a gross profit of 26% is required to maintain a viable pharmacy
and said that he had found that some pharmacies
with a higher gross profit were
not viable and others with a lower one were. (This has nothing to do with the
present question.)
He did not deal at all with the Lexecon report and as far as
Jordaan is concerned, he simply said that there were uncertainties with
the
analysis without identifying them. He added, without substantiating the
allegation, that the prescribed dispensing fees do not
differ significantly from
those in other countries. Prof Mossialos expressed a similar opinion, namely
that the fee is ‘quite
reasonable by international standards’ but he
also gave no factual basis for his opinion. Prof Henry, also from Australia,
let
the proverbial cat out of the bag when he said that the committee (of which he
was a member) was ‘concerned primarily about
the affordability’. He
gave no indication that the viability of the dispensing profession was ever
considered. He conceded
that it is difficult to make a judgment of the
appropriate level for a dispensing fee and he then made some international
comparisons.[75] Australia, for
instance, allows a dispensing fee equal to R23,00 but then it allows an
additional retail margin. Because the result
of the comparison did not suit him,
he made adjustments, taking into account the purchasing power of the two
currencies.
[87] The last witness for the respondents on this aspect was
Dr Thiede, the deputy director of the Health Economics Unit at the University
of
Cape Town. He was also a member of the committee and he, too, in spite of his
expertise, chose to keep everyone in the dark as
to how the fees were
calculated. He questioned Jordaan’s evidence because the sample was not
random, the allocation between
back-shop and front-shop could only have been
approximate and he could not on the facts provided make a
recalculation.
[88] In a separate affidavit he took brief issue with the
Lexecon report. Basic to his evidence is that he believed
‘that the
dispensing fee is only one fee in a catalogue of fees the pharmacist may charge,
such as for example for compounding.’
(I have already pointed out that
this assumption is flawed.) What other fees he had in mind, is unclear, unless
he thought that functions
like taking blood pressure (which have always been
done free of charge) could provide an income stream. He also did not attempt to
quantify that kind of income which, on the evidence, is negligible (less than
1%). He further, blandly, attacked the expertise of
Stillman, and stated without
motivation that the methodology did not conform to rigorous scientific studies
and that the sample was
not a random one. The reply indicated that he was
misinformed. It is significant that he nowhere gave any factual data to dispel
the applicants’ evidence.
[89] This brief analysis of the evidence
on record shows that there is no bona fide dispute of fact. It establishes that
the fees
are not appropriate and that the respondents, within whose peculiar
knowledge the calculation fell, were unable to give any rational
explanation for
the quantum of the fees. The access to medicines is seriously threatened because
they are insufficient to cover the
cost of dispensing. This conclusion is not
based on the opinion of pharmacists but on the unassailed factual material on
record.
It is not without significance that the Congress of SA Trade Unions, the
Consumer Goods Council and the amicus curiae came to the same
conclusion.
[90] There appears to be an explanation for the inability of
the respondents to justify the fees. It flows from the fact that the
different
functions of the department and those of the committee were not kept in mind,
and the working methods of the committee.
According to the Act, the committee
has to make the recommendations. The only function the department has until a
report is presented
to the minister is that of the committee’s
secretariat.
[91] After the draft regulations were published, the
committee decided that oral representations by stakeholders should be organised
by the department. These were to be led by the department, ‘but the
Pricing Committee members will also be invited.’
In consequence of the
decision the director-general invited stakeholders to make oral presentations.
The terms of the letter are
revealing (I quote selectively):
‘The
purpose of these sessions is to hear oral representations from stakeholders and
to give them an opportunity to fully canvass
their concerns and comments
regarding the proposed regulations. There will be no negotiation or debates
between the Department or the Committee on the one hand and yourselves on
the other concerning the proposed regulation.’
‘The Pricing
Committee is a technical committee whose task is to make recommendations to the
Minister of Health. You are therefore
advised to prepare your written and oral
inputs in as much detail as possible and with a view to supplying accurate and
substantiated
information to the Department and the Pricing Committee on
how the proposed regulations may affect your interests.’
‘Only
members of the Pricing Committee and officials from the Department of Health
will be attending. Not all members of the
Pricing Committee may be able to
attend every session due to other commitments.’
[Emphasis
added.]
[92] Days were set aside for this purpose. Sometimes committee
members attended, sometimes not, sometimes haphazardly. Many stakeholders
made
detailed oral presentations (with visuals) on the effect of the proposed fees.
Was this a presentation to the department or
to the committee? The second
respondent, justifying the fact that the committee did not consider the oral
representations, said it
was to the department. For what purpose, she did not
say because, as mentioned, the department had no function except a secretarial
one. Dr Zofuka, on behalf of the minister, unflinchingly said that the committee
considered ‘all the submissions and comments’
but elsewhere admitted
that they considered the written ones only. Yekiso J found no fault with these
perplexing events, holding
that there was nothing to show that the meetings were
‘formal meetings of the committee’ or that the committee was under
a
duty to afford stakeholders an opportunity to make oral representations. To my
mind the facts speak for themselves. There was no
reason to mislead stakeholders
by inviting them to participate in a futile exercise or to ignore relevant and
available material
during the committee’s deliberations. It is not
necessary for me to deal further with this aspect of the case because of the
finding that the regulations do not prescribe a dispensing fee that is
appropriate.
CONCLUSION
[93] Thus far the findings
are that the regulations have, on many material aspects, failed the test of
legality. Sometimes problems
arose as a result of the enabling Act, sometimes it
was because of a misunderstanding of the scope of the Act. The applicants allege
in addition that some of the provisions are vague and void for that reason and
they submit that there are instances of impermissible
delegation of powers where
matters, which should have been prescribed, have been left for the minister or
the director-general. Some
of these arguments cannot as be dismissed as easily
as the majority below was able to do and some cannot be accepted as the
dissenter
did, but for present purposes it is not necessary to deal with
them.
[94] The question whether ministerial regulations and the
recommendations of the committee could have been the subject of scrutiny
under
the Promotion of Administrative Justice Act 2 of 2000 formed a large part of the
judgments below. The majority held that they could not and the minority held
otherwise. Notwithstanding
they were agreed that the regulations had to
withstand the test of legality. The debate, consequently, has no bearing on this
judgment
and I prefer to refrain from commenting save for saying that I find it
unlikely that this Act, written in the light of the Constitution
and supposedly
written to codify administrative justice principles, reduced the level of
administrative justice.
[95] The amicus curiae, while
submitting that the regulations, at least as far as the dispensing fee is
concerned, are void, requested that any declaration
of invalidity should be
suspended to enable the committee to prepare a new set. There are a number of
problems in this regard. As
mentioned, s 22G save for minor amendments, has been
since 1997 on the statute book and was only brought into effect in 2004. That
may give an indication of the ability of the respondents to formulate
regulations within a reasonable period. As found, the regulations
are fatally
defective. It will be extremely difficult, if not impossible, to draft sensible
regulations unless the Act is amended.
The respondents did not, in their papers,
raise the possibility of a suspension and did not place any facts before the
court below
on which a decision to suspend can be made; neither did the
amicus curiae. The regulations have been in effect during May and then
after the judgment below, for less than four months. It is not as if a long
existing pricing regime is being upset or that existing rights are affected. In
short, the request does not satisfy the guidelines
laid down for a
suspension.[76]
ORDER
[96] The following order is
made:
1. Leave to appeal is granted in both applications.
2. The appeals
are upheld.
3. The first respondent is ordered to pay the costs, including
the costs of two counsel in each matter.
4. The order of the court below is
set aside and replaced with the following order in each application:
(a)
The ‘Regulations relating to a Transparent Pricing System for
Medicines and Scheduled Substances’ as published in GN R553
on 30 April
2004 are declared invalid and of no force and effect.
(b) The first
respondent is ordered to pay the costs of the applicant(s), including the
costs relating to the interim application, such costs to include the
costs of
two counsel.
_____________________
L T C HARMS
JUDGE OF
APPEAL
CONCUR:
NAVSA JA
MTHIYANE JA
BRAND JA
CLOETE
JA
[1] GN R553 GG 26304 of 30 April
2004. The date of commencement was 2
May.
[2] All dates are 2004 unless
otherwise indicated.
[3] Rolled
Steel Products (Holdings) Ltd v British Steel Corp [1986] 1 Ch 246 (CA)
310C-E.
[4] Eg National Union of
Metalworkers of SA v Jumbo Products CC [1996] ZASCA 87; 1996 (4) SA 735 (A) 738E-G.
[5] Which they did at close of the
registrar’s office on 29
November.
[6] S v Lifele
1962 (2) SA 527 (A) 531F. The context was
different.
[7] There was a rather
lame attempt in the respondents’ answering affidavits in the present
applications to show that the regulations
did not threaten the viability of the
dispensing profession but respondents’ counsel thought it best no to deal
with the allegations
during
argument.
[8] The members of this
court were, without any background, able to prepare the appeal within the
allotted time during the busiest part
of
term.
[9] In answer to a complaint
about my ruling, addressed to the Acting President of the court, he pointed out
that the respondents were
entitled to apply at the hearing for a postponement of
the ‘merits’, which they never did.
[10] Of the seven counsel who
appeared on behalf of the respondents in the court below, three appeared before
us. One of these was a member
of the pricing committee, which was responsible
for the draft regulations.
[11]
Uniform rule 33(4) does not apply to the
SCA.
[12] See Chevron
Engineering (Pty) Ltd v Nkambule para 20; and American Natural Soda
Corporation v Competition Commission para
1.
[13] Moch v Nedtravel (Pty)
Ltd t/a American Express Travel Service 1996 3 SA 1 (A)
7F-G.
[14] Constitution s 168(3);
S v Basson [2004] ZACC 13; 2004 (6) BCLR 620 (CC) para
103.
[15] Moch v Nedtravel
(Pty) Ltd t/a American Express Travel Service 1996 3 SA 1 (A) 7F-G. See also
Sefatsa v Attorney-General, Transvaal 1989 (1) SA 821 (A)
834E.
[16] 2004 (6) BCLR 620
(CC).
[17] The only exclusion is
in s 20(7) which deals with certain matrimonial
disputes.
[18] S v Rens
1996 (1) SA 1218 (CC) para 7; Cronshaw v Coin Security Group (Pty) Ltd
[1996] ZASCA 38; 1996 (3) SA 686 (A) 689B.
[19]
The amendment was introduced by the Appeals Amendment Act 105 of
1982.
[20] That court must also
consider whether the appeal should be to the full court or this court. Since
these matters were heard in the
first instance by a full bench of three members,
an appeal to the full court was not
possible.
[21] Eg Middelberg v
Prokureursorde, Transvaal 2001 (2) SA 865 (SCA) para
5.
[22] Appellate Division
Further Jurisdiction Act 1 of 1911 s
3(b).
[23] But see De Beer v
Minister of Posts and Telegraphs 1922 AD
175.
[24] Oliff v Minnie
1953 (1) SA 1 (A).
[25] The
ultimate decision was reported as Sita v Olivier NO 1967 (3) SA 597
(A).
[26] Gentiruco AG v
Firestone SA (Pty) Ltd 1972 (1) SA 589 (A)
608E-G.
[27] Whether the right is
implicit does not arise. Cf s
35(3)(c).
[28] Cf Besserglik v
Minister of Trade, Industry and Tourism (Minister of Justice
intervening)[1996] ZACC 8; 1996 (4) SA 331 (CC) para 9-10.
[29] Cf s 35(3)(d) and (o) of the
Constitution. The European Convention on Human Rights provides in art 6(1) that
‘In the determination
of his civil rights and obligations ..., everyone is
entitled to a ... hearing within a reasonable time by [a] tribunal ... .’
There are many judgments on the article and reasonableness is assessed
particularly in the light of the circumstances of the case,
having regard in
particular to the complexity of the case and the conduct of the parties to the
dispute and the relevant authorities.
Terranova v Italy (ECHR)
4 December 1995, Series A no. 337-B
para. 20).
[30] In S v Venter 1999
(2) SACR 231 (SCA) the trial court took eight months to enroll the application
for leave to appeal. The applicant had been sentenced to 4 years
effective
imprisonment. He was in prison and on appeal his sentence was reduced to six
months. A clear failure of justice due to
judicial
delay.
[31] See s 173 of the
Constitution, which deals with this court’s inherent power to regulate and
protect its own process.
[32]
Boodhoo & Ors v. Attorney General of Trinidad and Tobago (Trinidad and
Tobago) [2004] UKPC 17 (PC) para
14.
[33] This court as a rule
disposes of applications for leave without oral argument and without providing
any reasons: Mphahlele v First National Bank of South Africa Ltd 1999 (3)
BCLR 253 (CC).
[34] Cf
Minister of Public Works v Kyalami Ridge Environmental Association 2001
(3) SA 1151 (CC) para 27.
[35] He
did not comment, maybe because he was unaware that the respondents had
approached the Acting Chief Justice to determine what dates
were available
there.
[36] S v Makwanyane
[1995] ZACC 3; 1995 (6) BCLR 665, 1995 (3) SA 391 (CC) para 225:‘Respect for the dignity
of every person is integral to this concept.’ Para 237: ‘The concept
carries
in it the ideas of humaneness, social justice and fairness.’ Para
263: ‘“The need for ubuntu” expresses the ethos of an
instinctive capacity for and enjoyment of love towards our fellow men and women;
the joy and the
fulfilment involved in recognizing their innate humanity; the
reciprocity this generates in interaction within the collective community;
the
richness of the creative emotions which it engenders and the moral energies
which it releases both in the givers and the society
which they serve and are
served by.’ Para 308: ‘Generally, ubuntu translates as
“humaneness”. ... in its fundamental sense it denotes humanity and
morality.’
[37] Botha v
White 2004 (3) SA 184; [2003] 2 All SA 362 (T) para
55.
[38] The protocol issued in
2003 by the Chief Justice and Judges of the Supreme Court of Tasmania
out what the local position has been since time immemorial:
‘1. The
policy of the Court is that judgment should be delivered as expeditiously as
possible. However, given (inter alia) the
constantly changing and often
unpredictable demands on judicial time, the differences in the priorities for
the delivery of judgments
in different cases and the difference in the time
required for the writing of judgment in different cases, the judges do not
regard
it as appropriate or useful to settle a time-table governing the delivery
of reserved judgments.
2. It is the Court's view that it is highly desirable
that the Court is always informed if there is some special reason why judgment
should be delivered quickly in a particular case and the Court has never seen
any objection to solicitors for the parties making
an enquiry in appropriate
cases as to when a reserved judgment might be expected to be delivered.
3. In
the event that the solicitors for one or more of the parties are concerned at
the delay in any given case, an enquiry in writing
may be made to the Judge in
question or to his Associate as to when judgment may be expected.
4. If the
enquiry is not answered to the satisfaction of the solicitor or the client, the
enquiry should be directed to the Chief
Justice, who will then consult with the
Judge who has reserved judgment.
5. If the delay is that of the Chief
Justice, the enquiry should be made to the Senior Puisne Judge.
6. If any
solicitor is reluctant to make a direct approach as set out above, he or she
should write to the President of the Tasmanian
Bar Association in confidence
advising details of the proceeding number, the parties, the name of the Judge
and the date of reservation.
The President will then write to the Chief Justice
(or Senior Puisne Judge) without identifying the solicitor on whose behalf the
enquiry is made and the Chief Justice (or Senior Puisne Judge) will then consult
with the Judge who has reserved judgment.
7. After consultation with the
Judge who has reserved judgment, the Chief Justice (or Senior Puisne Judge) will
respond to the President's
enquiry for forwarding to the solicitor making the
original enquiry.
8. This Protocol is similar to one operating in Victoria,
which is said to have operated satisfactorily from its inception. It is
made in
response to a request from the Tasmanian Bar
Association.’
[39]
‘Ethical guidelines for judges’ para 17 published at 117 (2000)
SALJ 406. These guidelines were adopted by the heads of court and apply
to all judges.
[40] Boodhoo
& Ors v. Attorney General of Trinidad and Tobago (Trinidad and Tobago)
[2004] UKPC 17 (PC).
[41] The Law
Times Reports (Feb 19, 1998) 85 at
86.
[42] They are not the first
to do so: Letterstedt v Morgan (1849) 5 Searle
373.
[43] Constitution s
165(4).
[44] Pharmaceutical
Manufacturers Association of SA: In re Ex parte President of the RSA [2000] ZACC 1; 2000
(3) BCLR 241; 2000 (2) SA 674 (CC) para
50.
[45] Para 17. He referred to
Fedsure Life Assurance Ltd v Greater Johannesburg Transitional Metropolitan
Council [1998] ZACC 17; 1998 (12) BCLR 1458; 1999 (1) SA 374 (CC) para 56-59 and
President of the Republic of South Africa and Others v South African Rugby
Football Union and Others 2000 (1) SA 1; 1999 (10) BCLR 1059 (CC). See also
Minister of Home Affairs v Eisenberg [2003] ZACC 10; 2003 (8) BCLR 838; 2003 (5) SA 281
(CC) para 39.
[46] Executive
Council of the Western Cape Legislature v President of the RSA [1995] ZACC 8; 1995 (10)
BCLR 1289; 1995 (4) SA 877 (CC) para
99.
[47] At para
100.
[48] Soobramoney v
Minister of Health, KwaZulu-Natal 1998 (1) SA 765, 1997 (12) BCLR 1696
(CC).
[49] Minister of Health
v Treatment Action Campaign (2) [2002] ZACC 15; 2002 (10) BCLR 1033; 2002 (5) SA 721 (CC)
para 46.
[50] Drugs Control
Amendment Act 65 of 1974 s
35.
[51] Administrator, Cape v
Raats Röntgen and Vermeulen (Pty) Ltd [1991] ZASCA 126; 1992 (1) SA 245 (A) 254B-G;
Mistry v Interim Medical and Dental Council of SA [1998] ZACC 10; 1998 (7) BCLR 880; 1998
(4) SA 1127 (CC) para 10-11.
[52] Pharmaceutical
Manufacturers Association of SA: In re Ex parte President of the RSA 2000
(3) BCLR 241; 2000 (2) SA 674
(CC).
[53] Medicines and Related
Substances Act 59 of 2002 s
14.
[54] For purposes of this
judgment reference will not be made to ‘related substances’.
[55]
‘”Importer” means a person importing medicines for the purpose
of sale in the Republic from a manufacturer or other
person outside of the
Republic and includes a parallel importer as defined in the
Act.’
[56] The full
definition reads: ‘“Single exit price” means the price set by
the manufacturer or importer of a medicine or Scheduled substance in
terms of these regulations combined with the logistics fee and VAT and is the
price of the
lowest unit of the medicine or Scheduled substance within a pack
multiplied by the number of units in the pack.’ [Emphasis
added.]
[57] The regulations
define ‘wholesaler’ as ‘a dealer who purchases
medicines or Scheduled substances from a manufacturer and sells them to a
retailer and includes a wholesale pharmacy.’ [Underlining added.]
[58] The second respondent,
according to her affidavit, thought that the transparent pricing system as
contemplated by the Act included
a logistics fee. She may have been confusing
the regulations with the
Act.
[59] Per the
director-general, Mr Ntsaluba, in previous litigation under
oath.
[60] Per Yekiso J:
‘It is worth repeating that the single exit price referred to in the Act
and the Regulations is set by the manufacturer
or the importer of the relevant
medicine or Scheduled substance. The single exit price has to be set by the
manufacturer or the
importer concerned.’
[61] Reg 5(2)(c)
proviso.
[62] Reg
5(2)(e).
[63] Reg
5(2)(e).
[64] Regs 5(2)(a) and
(b), 7 and 8.
[65] At para
53.
[66] Cf Goldberg v
Minister of Prisons 1979 (1) SA 14 (A)
48E.
[67] Reg 3: ‘In order
to promote transparency in the pricing of medicines . . . a manufacturer or . .
. the importer of a medicine
. . . shall publish, where applicable, the
following information in such manner and format, at such time intervals, upon
such conditions
and in such media as may be determined by the
Director-General from time to time by notice in the Gazette.’
[Emphasis added.]
[68] This is
the result of a 2002
amendment.
[69] SA Defence and
Aid Fund v Minister of Justice 1967 (1) SA 31 (C) 34H-35D; President of
the Republic of South Africa v South African Rugby Football Union1 2000 (1)
SA 1 (CC) para 168 footnote
132.
[70] Shorter
OED.
[71] The text of her speech
forms part of the papers.
[72]
The applicants estimate that the private sector’s expenditure on medicines
accounts for 70% and the state’s for 30% of
all funds spent. On the other
hand, the private sector consumes 30% and the state 70% by volume. This
indicates the great discrepancy
between the two systems, something the
Competition Commission is concerned about. The respondents deny these estimates
but do not
explain their
denial.
[73] It is possible that
the committee had worked on the fact that the average gross profit of pharmacies
was about 25% and then conflated
gross profit with
mark-up.
[74] Yekiso J found that
since the regulations under the Pharmacy Act do not recognize courier pharmacies
as a separate category for registration purposes, the pricing regulations could
not cater for them.
I disagree. These regulations could easily have categorized
pharmacies for its own purposes and the committee was not bound by another
classification for other
purposes.
[75] Whether the fee is
lower in, say, Botswana, does not indicate whether the public there has
reasonable access to dispensers or whether
the bulk of medicines is supplied by
the state.
[76] Mistry v
Interim Medical and Dental Council of SA 1998 (4) SA 1127 (CC) para 37.

RTF format